Top Page
Sinopharm Group Co
(1099)
Sinopharm Group Co (1099) vs. iShares MSCI Hong Kong ETF (EWH)
Sinopharm Group Co Business Overview & Revenue Model
Sinopharm Group Co Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 575.82B | 584.51B | 596.57B | 552.15B | 521.05B | 456.41B |
| Gross Profit | 43.09B | 44.26B | 48.51B | 47.43B | 44.05B | 40.32B |
| EBITDA | 20.58B | 20.17B | 26.90B | 26.25B | 24.68B | 22.62B |
| Net Income | 6.80B | 7.05B | 9.05B | 8.53B | 7.76B | 7.19B |
Balance Sheet | ||||||
| Total Assets | 420.17B | 392.83B | 383.39B | 364.78B | 335.41B | 311.24B |
| Cash, Cash Equivalents and Short-Term Investments | 47.16B | 54.31B | 63.81B | 55.22B | 43.54B | 50.22B |
| Total Debt | 93.29B | 76.39B | 73.78B | 69.59B | 68.37B | 68.53B |
| Total Liabilities | 290.70B | 266.14B | 263.08B | 254.71B | 235.76B | 221.29B |
| Stockholders Equity | 80.38B | 78.88B | 74.58B | 68.07B | 61.89B | 56.36B |
Cash Flow | ||||||
| Free Cash Flow | 16.32B | 9.58B | 14.84B | 18.55B | 7.05B | 9.07B |
| Operating Cash Flow | 18.43B | 11.55B | 17.17B | 20.96B | 9.31B | 11.15B |
| Investing Cash Flow | -3.24B | -3.75B | -944.53M | -3.59B | -1.27B | -2.20B |
| Financing Cash Flow | -23.26B | -17.29B | -7.64B | -5.69B | -14.69B | 2.03B |
Sinopharm Group Co Technical Analysis
Sinopharm Group Co Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
72 Outperform | $60.53B | 8.24 | 8.74% | 3.70% | -2.68% | -21.45% | |
71 Outperform | $65.17B | 7.24 | 7.53% | 2.65% | 2.77% | 39.24% | |
58 Neutral | HK$9.68B | 51.47 | 5.07% | 1.36% | 0.33% | -44.28% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
Sinopharm Group Co Corporate Events
Sinopharm Group Co. Ltd. announced its unaudited financial results for the third quarter of 2025, showcasing a revenue of RMB 13.75 billion, marking a 3.58% increase compared to the same period last year. The net profit attributable to shareholders rose by 13.10% to RMB 543.72 million, although the net cash flow from operating activities was negative at RMB -2.05 billion. These results indicate a stable revenue growth and profitability, despite challenges in cash flow, which could impact the company’s operational liquidity and stakeholder confidence.
The most recent analyst rating on (HK:1099) stock is a Buy with a HK$21.00 price target. To see the full list of analyst forecasts on Sinopharm Group Co stock, see the HK:1099 Stock Forecast page.
Sinopharm Group Co. Ltd. announced the preliminary financial data for its subsidiary, Sinopharm Accord, for the nine months ending September 30, 2025. The report indicates a slight decrease in total revenue and net profit compared to the previous year, with total revenue down by 2.38% and net profit attributable to shareholders decreasing by 10.18%. Despite the decline in profits, the company saw an increase in total assets by 6.31% and equity attributable to shareholders by 4.30%, suggesting a stable financial position. These results may impact the company’s market positioning and stakeholder confidence, as they reflect both challenges and resilience in the current economic climate.
The most recent analyst rating on (HK:1099) stock is a Buy with a HK$21.00 price target. To see the full list of analyst forecasts on Sinopharm Group Co stock, see the HK:1099 Stock Forecast page.
Sinopharm Group Co. Ltd. has announced that its board of directors will hold a meeting on October 24, 2025, to consider and approve the unaudited quarterly results for the nine months ending September 30, 2025. This meeting is crucial for stakeholders as it will provide insights into the company’s financial performance and strategic direction, potentially impacting its market positioning and investor confidence.
The most recent analyst rating on (HK:1099) stock is a Hold with a HK$20.50 price target. To see the full list of analyst forecasts on Sinopharm Group Co stock, see the HK:1099 Stock Forecast page.
Sinopharm Group Co. Ltd. announced the unaudited financial results for its subsidiary, Sinopharm Accord, for the first half of 2025. The company reported a slight decrease in revenue by 2.62% to RMB 36.8 billion and a 10.43% drop in net profit attributable to shareholders. The net cash flow from operating activities significantly declined by 98.38%, indicating potential operational challenges. Despite these declines, total assets increased by 6.04%, reflecting some growth in asset base. The announcement may impact stakeholders’ perception of the company’s financial health and operational efficiency.
The most recent analyst rating on (HK:1099) stock is a Buy with a HK$20.50 price target. To see the full list of analyst forecasts on Sinopharm Group Co stock, see the HK:1099 Stock Forecast page.
Sinopharm Group Co. Ltd., a leading pharmaceutical distribution company in China, is primarily engaged in the distribution of pharmaceutical products, medical devices, and the operation of chain pharmacy stores. The company operates in the healthcare sector and is known for its extensive distribution network and comprehensive service offerings.
Sinopharm Group Co. Ltd. has announced its unaudited interim results for the first half of 2025, showing a decrease in revenue and profit compared to the same period last year. Despite a reduction in costs, the company experienced a decline in gross profit and operating profit, reflecting challenges in maintaining its financial performance amidst market conditions.
The most recent analyst rating on (HK:1099) stock is a Buy with a HK$22.50 price target. To see the full list of analyst forecasts on Sinopharm Group Co stock, see the HK:1099 Stock Forecast page.
Sinopharm Group Co., Ltd. has released the unaudited financial data for its subsidiary, China National Medical Device Co., Ltd. (CNMDC), for the first half of 2025. The report shows a slight decline in revenue and operating profit compared to the previous year, with revenue down by 1.48% and operating profit by 8.28%. However, total comprehensive income attributable to the parent company saw a marginal increase of 1.02%. Notably, the net cash flow from operating activities improved significantly, reducing the deficit by 67.88%. The company’s total assets and equity attributable to owners also saw growth, indicating a stable financial position despite the challenges. This financial update may impact stakeholders’ perceptions of CNMDC’s market positioning and operational efficiency.
The most recent analyst rating on (HK:1099) stock is a Buy with a HK$21.50 price target. To see the full list of analyst forecasts on Sinopharm Group Co stock, see the HK:1099 Stock Forecast page.
Sinopharm Group Co. Ltd. announced its unaudited financial results for the first half of 2025, revealing a slight decrease in total assets by 0.37% and a modest increase in net assets attributable to shareholders by 2.02%. Revenue grew by 3.54% compared to the same period last year, while total profit and net profit attributable to shareholders declined by 6.92% and 5.19% respectively. The company also reported a negative net cash flow from operating activities, indicating potential cash management challenges. These financial indicators suggest a mixed performance, with growth in revenue but a decline in profitability, which may impact the company’s market positioning and stakeholder confidence.
The most recent analyst rating on (HK:1099) stock is a Buy with a HK$21.50 price target. To see the full list of analyst forecasts on Sinopharm Group Co stock, see the HK:1099 Stock Forecast page.
Sinopharm Group Co. Ltd. announced preliminary financial results for its subsidiary, Sinopharm Accord, for the first half of 2025, showing a slight decline in revenue and profit compared to the same period last year. Despite a decrease in net profit and earnings per share, the company’s total assets and equity attributable to shareholders saw an increase, indicating a stable financial position amidst challenging market conditions.
The most recent analyst rating on (HK:1099) stock is a Buy with a HK$29.30 price target. To see the full list of analyst forecasts on Sinopharm Group Co stock, see the HK:1099 Stock Forecast page.
Sinopharm Group Co. Ltd. has announced that its board of directors will meet on August 22, 2025, to consider and approve the unaudited interim results for the first half of the year. This meeting is crucial as it will provide insights into the company’s financial performance and strategic direction, potentially impacting its market positioning and stakeholder interests.
The most recent analyst rating on (HK:1099) stock is a Buy with a HK$29.30 price target. To see the full list of analyst forecasts on Sinopharm Group Co stock, see the HK:1099 Stock Forecast page.